Showing 3121-3130 of 3223 results for "".
- VSP Global Announces Executive Team Appointmentshttps://modernod.com/news/vsp-global-announces-executive-team-appointments/2479797/VSP Global announced the appointments of Earnie Franklin as chief technology officer (CTO), and Alec Mahmood as chief financial officer (CFO). Mr. Franklin and Mr. Mahmood will report to Michael Guyette, VSP Global’s president and CEO. “I am thrilled to welcome these two phenomenal l
- Staar Surgical Announces Agreement with Dr. Tobias Neuhann in Germany to Create Collaboration with Single Site Ophthalmology Clinicshttps://modernod.com/news/staar-surgical-announces-agreement-with-dr-tobias-neuhann-in-germany-to-create-collaboration-with-single-site-ophthalmology-clinics/2479798/Staar Surgical announced a multi-year strategic alliance agreement with Tobias Neuhann, MD, of the Augenklinik am Marienplatz (Eye Clinic at Marienplatz) in Munich, Germany. The agreement serves as a global partnership model for smaller and single site refractive surgery eye clinics that aim to p
- EMA Accepts Drug Application for Regulatory Approval of Rhokiinsa (Rhopressa)https://modernod.com/news/ema-accepts-drug-application-for-regulatory-approval-of-rhokiinsa-rhopressa/2479802/Aerie Pharmaceuticals reported that the European Medicines Agency (EMA) has accepted for review the MAA for Rhokiinsa (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa in the United States and is indicated for the reduction of elevated IOP in patients with open-
- Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-campaign-to-spotlightsight-in-honor-of-world-sight-day/2479805/Sight is the most prized of all human senses. Yet, there are many people who do not fully experience the wonder of this gift. Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment. That’s why Johnson
- Optikon Introduces R-Evo Smart for Cataract and Retinal Surgeryhttps://modernod.com/news/optikon-introduces-r-evo-smart-for-cataract-and-retinal-surgery/2479806/Optikon has introduced R-Evo smart, a compact platform that allows anterior and posterior segment surgeries to be performed with the same cassette. The R-Evo equipment is available in disposable and reusable versions.
- Zeiss Receives FDA Approval for ReLEx SMILE for Myopia With Astigmatismhttps://modernod.com/news/zeiss-receives-fda-approval-for-astigmatism-indication-for-relex-smile/2479812/Zeiss announced the FDA premarket approval for ReLEx SMILE to treat myopia with astigmatism. The premarket approval also provides for a small entry incision to be made, allowing the
- Regenxbio Completes Dosing of Fourth Cohort in Phase 1 Trial of RGX-314 Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-dosing-of-fourth-cohort-in-phase-1-trial-of-rgx-314-gene-therapy-for-wet-amd/2479815/Regenxbio announced it has completed dosing of the fourth cohort of six patients in a phase 1 clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (AMD). A total of 24 subjects have been dosed in the trial. The company also announced that an updated summary
- Fluocinolone Acetonide Implant Effective for Refractory Diabetic Macular Edemahttps://modernod.com/news/fluocinolone-acetonide-implant-effective-for-refractory-diabetic-macular-edema/2479818/Most patients with chronic diabetic macular edema (DME) who received a fluocinolone acetonide intravitreal implant did not require additional therapy to lower their intraocular pressure (IOP), according to a registry safety study of the implant (Iluvien, Alimera Sciences), according to a Reuters
- Statins, Fibrates Lower Diabetic Retinopathy Risks in Diabeteshttps://modernod.com/news/statins-fibrates-lower-diabetic-retinopathy-risks-in-diabetes/2479824/The use of lipid-lowering medication with fibrates, including fenofibrate (Lipidil, Abbott), and statins reduces not only the incidence of diabetic retinopathy in patients with type 2 diabetes but also the need for treatment in those who already have the condition, indicates a real-world J
- ASCRS Releases Preliminary CyPass Withdrawal Consensus Statementhttps://modernod.com/news/ascrs-releases-preliminary-cypass-withdrawal-consensus-statement/2479843/The American Society of Cataract and Refractive Surgery convened a CyPass Withdrawal Task Force to review the data from the COMPASS-XT study and related research and develop an independent physician guidance document associated with the voluntary withdrawal of Alcon’s CyPass Micro-Stent. To